Last reviewed · How we verify
Matching Placebo to Fidaxomicin — Competitive Intelligence Brief
phase 3
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Matching Placebo to Fidaxomicin (Matching Placebo to Fidaxomicin) — Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). This is a placebo formulation designed to match the appearance and administration characteristics of fidaxomicin for blinded clinical trial comparison.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Matching Placebo to Fidaxomicin TARGET | Matching Placebo to Fidaxomicin | Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Matching Placebo to Fidaxomicin CI watch — RSS
- Matching Placebo to Fidaxomicin CI watch — Atom
- Matching Placebo to Fidaxomicin CI watch — JSON
- Matching Placebo to Fidaxomicin alone — RSS
Cite this brief
Drug Landscape (2026). Matching Placebo to Fidaxomicin — Competitive Intelligence Brief. https://druglandscape.com/ci/matching-placebo-to-fidaxomicin. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab